Opinion|Videos|December 17, 2025
Assessing Overall Survival and Safety Data
Because ASCENT-03 allowed crossover and more than half of patients received subsequent therapy, overall survival is unlikely to show a statistically significant difference, even if a clinical benefit exists.
Advertisement
Episodes in this series
Because ASCENT-03 allowed crossover and more than half of patients received subsequent therapy, overall survival is unlikely to show a statistically significant difference, even if a clinical benefit exists. Clinicians often interpret the survival data in this context, recognizing that progression-free survival and duration of response may better reflect the true treatment effect. Safety data revealed the importance of prophylaxis with G-CSF and the importance of pharmacists in monitoring for adverse events.
Advertisement
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
4
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
5